Cargando…

Use of Defibrotide in Patients with COVID-19 Pneumonia; Results of the Defi-VID19 Phase 2 Trial

Background: The clinical spectrum of COVID-19 ranges from pauci-symptomatic forms to severe disease characterized by respiratory failure requiring mechanical ventilation and intensive care unit (ICU) management, as well as multisystem involvement characterized by sepsis, organ dysfunction and death....

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruggeri, Annalisa, Voza, Antonio, Liberatore, Carmine, Catalano, Gloria, Corrado, Francesco, Di Filippo, Luigi, Nitti, Rosamaria, Fedeli, Carlo, Bruno, Alessandro, Calabretta, Eleonora, Giglio, Fabio, Sciutti, Fabio, Lunghi, Francesca, Landoni, Giovanni, Richardson, Paul G., Iacobelli, Massimo, Aghemo, Alessio, Rovere-Querini, Patrizia, Assanelli, Andrea A., Peccatori, Jacopo, Ciceri, Fabio, Carlo-Stella, Carmelo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology. Published by Elsevier Inc. 2021
Materias:	332.Anticoagulation and Antithrombotic Therapies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701766/ http://dx.doi.org/10.1182/blood-2021-147784

Ejemplares similares

Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group
por: Moraleda, Jose M., et al.
Publicado: (2020)

Defibrotide Therapy for Sars CoV2 Acute Respiratory Distress Syndrome
por: Yanik, Gregory A, et al.
Publicado: (2021)

Edoxaban Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Hospitalized Patients with Atrial Fibrillation and COVID-19 Infection
por: Olivera, Pável E, et al.
Publicado: (2020)

Increasing Doses of Anticoagulation Are Associated with Improved Survival in Hospitalized COVID-19 Patients
por: Ionescu, Filip, et al.
Publicado: (2020)

COVID-19 Associated Coagulopathy: Thrombosis, Hemorrhage and Mortality Rates with an Escalated-Thromboprophylaxis Strategy
por: Daughety, Molly, et al.
Publicado: (2020)

COVID-19-Associated Coagulopathy: Safety and Efficacy of Prophylactic Anticoagulation Therapy in Hospitalized Adults with COVID-19
por: Chambers, Isaac, et al.
Publicado: (2020)

Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis
por: Goshua, George, et al.
Publicado: (2020)

Thrombotic Complications in a Canadian Population of Critically Ill Patients with COVID-19
por: Camille, Simard, et al.
Publicado: (2020)

Filter Clotting with Continuous Renal Replacement Therapy in COVID-19
por: Rosovsky, Rachel P., et al.
Publicado: (2020)

Anticoagulation Management and Outcomes in Covid-19 Patients:a Multi-Center Retrospective Cohort Study
por: Kaur, Jasmeet, et al.
Publicado: (2020)

The Role of D-Dimer for Optimal Thromboprophylaxis Strategy in Patients with COVID-19
por: Bhoopat, Lantarima, et al.
Publicado: (2020)

The Potential Role of Therapeutic Dose of Low Molecular Weight Heparin (LWMH) to Attenuate Hyper-Inflammatory State in Hospitalized COVID-19 Patients
por: Mughal, Mohsin Sheraz, et al.
Publicado: (2020)

Outcomes in COVID-19 Patients on Treatment Dose Anti-Coagulation Compared to Prophylactic Dose Anti-Coagulation
por: Kodama, Rich, et al.
Publicado: (2020)

The Impact of Different Prophylactic Anticoagulation Doses on the Outcomes of Patients with COVID-19
por: Jiménez-Soto, Rodolfo, et al.
Publicado: (2020)

The Elevation of LIVER Enzymes in Patients with Atrial Fibrillation and COVID-19 Is a Marker of Bad Evolution and Mortality
por: Cerezo Manchado, Juan Jose, et al.
Publicado: (2020)

Evaluation of Antiplatelet and Anticoagulation Therapy in High-Risk COVID-19 Patients
por: Ashraf, Farah, et al.
Publicado: (2020)

Clinical Outcomes in Critically-Ill Patients with COVID-19 Treated with Therapeutic Dose of Anticoagulants for Suspected Thromboembolism
por: Naing, Phyu Thin, et al.
Publicado: (2021)

Targeting the Endothelium in the Treatment of COVID-19 Early Clinical Stages: Results of a Randomized Placebo-Controlled Trial
por: Gonzalez-Ochoa, Alejandro
Publicado: (2021)

Extended Thromboprophylaxis in Patients with COVID-19
por: Zhao, Wei, et al.
Publicado: (2021)

The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists
por: Visser, Chantal, et al.
Publicado: (2021)

Optimal Anticoagulant Dosing in Patients with COVID-19, a Retrospective Review
por: Carrillo, Alessandra, et al.
Publicado: (2021)

Rapid ECMO Training for Nurses in Response to the COVID-19 Pandemic
por: Toy, B., et al.
Publicado: (2021)

Role of Direct Oral Anticoagulants for Post-operative Venous Thromboembolism Prophylaxis
por: Tun, Han Naung, et al.
Publicado: (2022)

Defibrotide Prophylaxis of Sinusoidal Obstruction Syndrome in Adults Treated With Inotuzumab Ozogamicin Prior to Hematopoietic Stem Cell Transplantation
por: Giglio, Fabio, et al.
Publicado: (2022)

Perioperative Anticoagulation Management in Spine Surgery: Initial Findings From the AO Spine Anticoagulation Global Survey
por: Louie, Philip, et al.
Publicado: (2020)

Endothelial dysfunction and its critical role in COVID‐19‐associated coagulopathy: Defibrotide as an endothelium‐protective, targeted therapy
por: García‐Bernal, David, et al.
Publicado: (2021)

Immune Reconstitution-Based Score for Risk Stratification of Chronic Graft-Versus-Host Disease Patients
por: Serpenti, Fabio, et al.
Publicado: (2021)

Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide
por: Greco, Raffaella, et al.
Publicado: (2019)

Innovative Platforms for Haploidentical Stem Cell Transplantation: The Role of Unmanipulated Donor Graft
por: Ciceri, Fabio, et al.
Publicado: (2011)

Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer (RCC)
por: Bregni, Marco, et al.
Publicado: (2011)

Addition of a Single Low Dose of Anti T-Lymphocyte Globulin to Post-Transplant Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplant: A Pilot Study
por: Xue, Elisabetta, et al.
Publicado: (2022)

Defibrotide for hepatic veno-occlusive disease
Publicado: (2021)

Lung Ultrasound to Evaluate Invasive Fungal Diseases after Allogeneic Hematopoietic Stem Cell Transplantation
por: Raffaella, Greco, et al.
Publicado: (2019)

A Meta-Analysis Evaluating the Incidence of Bleeding Events With Intravenous Defibrotide Treatment Outside the Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Setting
por: Tappe, William, et al.
Publicado: (2020)

Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis
por: Ciceri, Fabio, et al.
Publicado: (2023)

Use of Defibrotide to help prevent post-transplant endothelial injury in a genetically predisposed infant with metachromatic leukodystrophy undergoing hematopoietic stem cell gene therapy
por: Calbi, Valeria, et al.
Publicado: (2018)

Trend towards reduction in COVID-19 in-hospital mortality
por: Ruggeri, Annalisa, et al.
Publicado: (2021)

Response to Maccio et al, “Multifactorial pathogenesis of COVID‐19‐related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?”
por: Richardson, Edward, et al.
Publicado: (2020)

Defying doom
por: Quinn, Bernardo
Publicado: (2016)

The Waves Defied
Publicado: (1875)

Cannot write session to /tmp/vufind_sessions/sess_kss3lg2nh4nj8vagtuc6smg7im